Search

Inetetamab

Inetetamab is a trastuzumab analog. It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

QR-333

QR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder … that can lead to numbness, skin ulcers, constant pain or extreme sensitivity to a stimulus.

Tezacitabine

A synthetic purine nucleoside analogue with potential antineoplastic activity.

XEN-2174

In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation of inhibitory pathways preventing pain signals from reaching the brain. … XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef.

(R)-warfarin

S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.[A1038] … Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.

Foralumab

Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).

ATG003

ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.

Brecanavir

Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV. … In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007.

Arginine glutamate

KOS-2187

KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease